When submitting, the first author must agree to register and present the abstract at the Meeting if it is selected for presentation. This includes being present during the scheduled time of a poster session. The first author may delegate an alternate presenter to attend in person if they are n...
in which oncologists agree to follow guidelines-driven treatment regimens agreed upon by consensus of their academic center, health plan, or practice network; (2) therapeutic interchanges, in which reimbursement models create incentives to promote lower-cost drugs, such as biosimilars; and (3) appr...
在本次盛会中,来自东南大学附属中大医院沈杨教授团队的“安罗替尼治疗晚期妇科肿瘤的有效性和安全性:一项真实世界研究”(Efficacy and safety of anlotinib in overall and disease-specific advanced gynecological cancer: A real-world stu...
(ftd/tpi) and bevacizumab (bev) in refractory metastatic colorectal cancer (mcrc): the betas trial. first author: nieves martinez lago text_snippet poster 2020 asco virtual scientific program talapro-2: a placebo-controlled phase iii study of talazoparib (tala) plus enzalutamide (enza) for ...
poster presentation at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. HLX208-LCH/ECD201 study was led by Professor Jian Li from Peking Union Medical College Hospital, Chinese Academy of Medical Scienc...
47.9%, 47.0%, and 5.1% of abstracts were accepted as online publication only, poster, and oral presentation, respectively. First authors were affiliated with institutions in native English-speaking countries (NESC) in 83 (70.9%) abstracts and non-native English-speaking countries (NNESC) in 34...
Oral Abstract and Poster Presenters' deadline to submit their presentation materials (slides, posters) on ASCO's Speaker Center Website LATE-MAY 2025 Majority of abstracts are released onasco.org/abstractsat 5:00 PM ET (Late-breaking Abstracts will be released at 7:00 AM CT on their day ...
2023 ASCO GU年会于2月16-18日在美国旧金山召开。一项替雷利珠单抗联合放疗作为BCG治疗无应答的高危NMIBC患者保膀胱治疗的II期研究结果在本次大会的尿路上皮癌专场以壁报的形式展示(Poster Board Number: K14)。我们特邀该研究的PI,来自中山大学肿瘤防治中心的刘卓炜教授对该研究进行深入解析与点评。
Sign in for customized ASCO content related to your areas of interest. Sign In Abstracts Guidelines Journal Articles Posters Videos & Slides Most Viewed Recommended For You
Recently, the latest clinical data of two Henlius products were released online and will be presented in poster sessions at the 2024 ASCO Gastrointestinal Cancers Symposium (ASCO GI), namely, the phase 2/3 study (HLX10-015-CRC301) of Henlius’ NMPA approved anti-PD-1 monoclonal antibody (mAb...